Mucosal Melanoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MCS004 MIFTS: 46	Mucosal Melanoma Categories: Cancer diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Mucosal Melanoma

MalaCards integrated aliases for Mucosal Melanoma:

Name: Mucosal Melanoma ¹² ²⁹ ¹⁵ ⁷⁰

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050929

UMLS ⁷⁰ C3898222

Sources

Summaries for Mucosal Melanoma

Disease Ontology : ¹² A melanoma that has material basis in melanocytes located in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract.

MalaCards based summary : Mucosal Melanoma is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and malignant skin fibrous histiocytoma. An important gene associated with Mucosal Melanoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cisplatin and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include mucosal membranes lining the respiratory, skin and lymph node, and related phenotypes are behavior/neurological and hematopoietic system

Wikipedia : ⁷³ Mucosal melanoma is a rare condition characterized by a melanoma of the mucous membranes. This subtype... more...

Sources

Related Diseases for Mucosal Melanoma

Diseases related to Mucosal Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)

#	Related Disease	Score	Top Affiliating Genes
1	vitiligo-associated multiple autoimmune disease susceptibility 1	30.5	MITF IL2 CD274
2	malignant skin fibrous histiocytoma	30.2	NRAS KIT IFNA2 GNAQ GNA11
3	malignant conjunctival melanoma	30.1	NRAS IFNA2 GNAQ GNA11
4	vulvar melanoma	30.1	NRAS NF1 KIT GNAQ GNA11
5	acral lentiginous melanoma	30.0	TERT NRAS KIT CDKN2A CD274 BRAF
6	mucositis	29.9	VEGFA IL2 IFNA1
7	li-fraumeni syndrome	29.7	TP53 TERT NF1 CDKN2A
8	merkel cell carcinoma	29.7	TP53 KIT CDKN2A CD274
9	dermatofibrosarcoma protuberans	29.7	TP53 KIT CDKN2A
10	exanthem	29.7	VEGFA KIT IL2 IFNA1 CD274
11	neutropenia	29.6	TP53 IL2 IFNA2 IFNA1
12	malignant anus melanoma	29.4	NRAS MAGEC2 MAGEC1 KIT IL2 GNA11
13	thrombocytopenia	29.3	TERT KIT IL2 IFNA2 IFNA1 CD274
14	squamous cell carcinoma	29.3	VEGFA TP53 CTAG1B CDKN2A BRAF
15	nodular malignant melanoma	29.1	TP53 NRAS MITF KIT GNAQ GNA11
16	rhabdomyosarcoma	28.9	VEGFA TP53 NRAS NF1 KIT CDKN2A
17	gastrointestinal stromal tumor	28.9	VEGFA TP53 NF1 KIT CDKN2A BRAF
18	neuroblastoma	28.6	VEGFA TP53 TERT NRAS NF1 KIT
19	kidney cancer	28.5	VEGFA TP53 IL2 IFNA2 IFNA1 CDKN2A
20	ocular melanoma	28.3	VEGFA TERT NRAS KIT IL2 GNAQ
21	melanoma	28.2	VEGFA TP53 TERT NRAS MITF MAGEC2
22	melanoma, cutaneous malignant 1	27.8	TP53 TERT NRAS NF1 MITF KIT
23	skin melanoma	27.7	VEGFA TP53 TERT NRAS NF1 MITF
24	melanoma, uveal	27.5	VEGFA TP53 TERT NRAS NF1 MITF
25	skin carcinoma	27.2	VEGFA TP53 TERT NRAS NF1 MITF
26	melanomatosis	10.5	NRAS GNAQ
27	phakomatosis cesioflammea	10.4	GNAQ GNA11
28	rare tumor	10.4
29	meningeal melanocytoma	10.4	GNAQ GNA11
30	conjunctival nevus	10.4	NRAS GNAQ
31	urachal adenocarcinoma	10.4	NF1 BRAF
32	acneiform dermatitis	10.4	NRAS BRAF
33	cervical adenoid cystic carcinoma	10.4	KIT CDKN2A
34	meningeal melanoma	10.4	NRAS GNAQ GNA11
35	meningeal melanomatosis	10.4	NRAS GNAQ GNA11
36	malignant leptomeningeal tumor	10.4	NRAS GNAQ GNA11
37	central nervous system melanocytic neoplasm	10.4	NRAS GNAQ GNA11
38	hypomelanosis of ito	10.3	NRAS GNAQ GNA11
39	epstein-barr virus-associated gastric carcinoma	10.3	CDKN2A CD274
40	laryngeal small cell carcinoma	10.3	KIT CDKN2A
41	primary cutaneous diffuse large b-cell lymphoma, leg type	10.3	CDKN2A CD274
42	maxillary sinus benign neoplasm	10.3	KIT CDKN2A
43	childhood acute myeloid leukemia	10.3	NRAS KIT IL2
44	plexiform schwannoma	10.3	NF1 KIT
45	myelodysplastic/myeloproliferative neoplasm	10.3	NRAS NF1 KIT
46	small intestine leiomyoma	10.3	NF1 KIT
47	gallbladder melanoma	10.3	MITF IL2
48	spermatocytoma	10.3	MAGEC1 KIT CTAG1B
49	corneal intraepithelial neoplasm	10.3	IFNA2 IFNA1
50	sturge-weber syndrome	10.3	NF1 GNAQ GNA11

Graphical network of the top 20 diseases related to Mucosal Melanoma:

Sources

Symptoms & Phenotypes for Mucosal Melanoma

MGI Mouse Phenotypes related to Mucosal Melanoma:

⁴⁶ (show all 26)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.44	BRAF CD274 CDKN2A GNA11 GNAQ IL2
2	hematopoietic system	MP:0005397	10.44	BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
3	growth/size/body region	MP:0005378	10.43	BAP1 BRAF CDKN2A GNA11 GNAQ IL2
4	immune system	MP:0005387	10.42	BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
5	cellular	MP:0005384	10.4	BAP1 BRAF CD274 CDKN2A IL2 KIT
6	endocrine/exocrine gland	MP:0005379	10.4	BAP1 BRAF CDKN2A GNA11 GNAQ IL2
7	homeostasis/metabolism	MP:0005376	10.4	BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
8	cardiovascular system	MP:0005385	10.36	BAP1 BRAF CDKN2A GNA11 GNAQ IL2
9	mortality/aging	MP:0010768	10.34	BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
10	craniofacial	MP:0005382	10.31	BRAF GNA11 GNAQ KIT MITF NF1
11	integument	MP:0010771	10.31	BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
12	digestive/alimentary	MP:0005381	10.3	BAP1 BRAF CDKN2A IL2 KIT NF1
13	embryo	MP:0005380	10.25	BAP1 BRAF CDKN2A KIT MITF NF1
14	liver/biliary system	MP:0005370	10.25	BRAF CDKN2A GNA11 IL2 KIT MITF
15	limbs/digits/tail	MP:0005371	10.22	BRAF GNA11 GNAQ KIT MITF NF1
16	neoplasm	MP:0002006	10.16	BAP1 BRAF CDKN2A IL2 KIT NF1
17	muscle	MP:0005369	10.13	BAP1 BRAF CDKN2A GNA11 GNAQ KIT
18	hearing/vestibular/ear	MP:0005377	10.12	BRAF GNA11 GNAQ KIT MITF NF1
19	normal	MP:0002873	10.1	BRAF GNA11 GNAQ KIT MITF NF1
20	no phenotypic analysis	MP:0003012	10.09	BAP1 CD274 CDKN2A IL2 KIT MITF
21	pigmentation	MP:0001186	10.02	BRAF CDKN2A GNA11 GNAQ KIT MITF
22	reproductive system	MP:0005389	9.96	BAP1 BRAF CDKN2A IL2 KIT MITF
23	respiratory system	MP:0005388	9.93	BAP1 BRAF CDKN2A GNA11 GNAQ IL2
24	renal/urinary system	MP:0005367	9.92	BRAF GNA11 GNAQ KIT MITF NF1
25	skeleton	MP:0005390	9.73	BRAF CD274 CDKN2A GNA11 GNAQ KIT
26	vision/eye	MP:0005391	9.28	BRAF CDKN2A IL2 KIT MITF NF1

Sources

Drugs & Therapeutics for Mucosal Melanoma

Drugs for Mucosal Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cisplatin

Approved

Phase 3

15663-27-1

84093 441203 2767

Temozolomide

Approved, Investigational

Phase 3

85622-93-1

5394

Dacarbazine

Approved, Investigational

Phase 3

4342-03-4

5351166 2942

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Carboplatin

Approved

Phase 3

41575-94-4

10339178 498142 38904

Sorafenib

Approved, Investigational

Phase 3

284461-73-0

216239 406563

Imidacloprid

Vet_approved

Phase 3

105827-78-9

86418

interferons

Phase 3

Interferon-alpha

Phase 3

Interferon alpha-2

Phase 3

Alkylating Agents

Phase 3

polysaccharide-K

Phase 3

Tubulin Modulators

Phase 3

Antimitotic Agents

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Axitinib

Approved, Investigational

Phase 2

319460-85-0

6450551

Durvalumab

Approved, Investigational

Phase 1, Phase 2

1428935-60-7

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Ceritinib

Approved

Phase 2

1032900-25-6

Dabrafenib

Approved, Investigational

Phase 2

1195765-45-7

44462760 44516822

Trametinib

Approved

Phase 2

871700-17-3

11707110

Pembrolizumab

Approved

Phase 2

1374853-91-4

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

6436030 5284616

Tyrosine

Approved, Investigational, Nutraceutical

Phase 2

60-18-4

6057

Tremelimumab

Investigational

Phase 1, Phase 2

745013-59-6

Vaccines

Phase 2

Imatinib Mesylate

Phase 2

220127-57-1

123596

Pharmaceutical Solutions

Phase 2

Apatinib

Phase 2

811803-05-1

Immunoglobulins, Intravenous

Phase 2

Endostar protein

Phase 2

Muromonab-CD3

Phase 1, Phase 2

Angiogenesis Inhibitors

Phase 2

Antiviral Agents

Phase 2

Protein Kinase Inhibitors

Phase 2

Antibiotics, Antitubercular

Phase 2

Immunosuppressive Agents

Phase 2

Anti-Bacterial Agents

Phase 2

Anti-Infective Agents

Phase 2

Immunologic Factors

Phase 2

Antifungal Agents

Phase 2

Interventional clinical trials:

(show all 30)

#	Name	Status	NCT ID	Phase	Drugs
1	A Multicenter, Randomized, Controlled, Phase III Trial Comparing High-Dose IFN-a2b With Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma	Unknown status	NCT03435302	Phase 3	Temozolomide Plus Cisplatin;High-Dose IFN-a2b
2	A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma	Completed	NCT00110019	Phase 3	Carboplatin;Paclitaxel;Sorafenib Tosylate
3	A Prospective Phase II Study in Patients With Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era	Unknown status	NCT03138642	Phase 2
4	A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma	Unknown status	NCT02023710	Phase 2	Paclitaxel;Carboplatin;Bevacizumab
5	A Phase II Trial of Dasatinib in KIT-Positive Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas	Completed	NCT00700882	Phase 2	dasatinib
6	A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.	Completed	NCT00424515	Phase 2	Imatinib
7	A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma	Completed	NCT01961115	Phase 2	Epacadostat
8	A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma	Completed	NCT01395121	Phase 2	nilotinib
9	Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)	Recruiting	NCT03235245	Phase 2	Nivolumab + Ipilimumab;Encorafenib + Binimetinib
10	A Randomized, Controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Axitinib in the First-Line Treatment of Patients With Advanced Mucosal Melanoma	Recruiting	NCT03941795	Phase 2	Axitinib 1 MG [Inlyta]
11	Phase II Clinical Study of CM082 Combined With JS001 in the Treatment of Advanced Mucosal Melanoma.	Recruiting	NCT03602547	Phase 2	CM082 plus JS001
12	Clinical Study of SHR-1210 Plus Apatinib in Patients With Advanced Mucosal Melanoma Whose Diseases Progress After Chemotherapy	Recruiting	NCT03986515	Phase 2	apatinib plus SHR-1210
13	Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252	Recruiting	NCT03241186	Phase 2	Ipilimumab;Nivolumab;Nivolumab
14	A Multicenter, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab(JS001) After Chemotherapy in Combination With Endostar in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma	Recruiting	NCT04472806	Phase 2	Toripalimab;chemotherapy in combination with Endostar
15	A Monocentric, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Localized Mucosal Melanoma	Recruiting	NCT04180995	Phase 2	TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)
16	Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma	Recruiting	NCT04318717	Phase 1, Phase 2	Pembrolizumab
17	Phase II Multicentric Study: Efficacy Evaluation of Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy on Disease-free-survival (DFS) in Patients With Resectable Head and Neck Mucosal Melanoma	Recruiting	NCT03313206	Phase 2	Pembrolizumab
18	A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma	Active, not recruiting	NCT02535078	Phase 1, Phase 2	IMCgp100;durvalumab;tremelimumab
19	A Phase II Randomized, Control, Multi-center Study of Recombinant Humanized Anti-PD-1 mAb for Injection Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery	Active, not recruiting	NCT03178123	Phase 2
20	Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma	Active, not recruiting	NCT04091217	Phase 2	Atezolizumab;Bevacizumab
21	A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma	Active, not recruiting	NCT02071940	Phase 2	PLX3397
22	A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Combined With Temozolomide and Cisplatin in the Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma	Enrolling by invitation	NCT04462965	Phase 2
23	Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma	Not yet recruiting	NCT02645149	Phase 2	Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care;CDK4/6 and MEK inhibitor
24	A Phase II Study of Neoadjuvant Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma	Not yet recruiting	NCT04622566	Phase 2	Lenvatinib, Pembrolizumab
25	A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6	Not yet recruiting	NCT04830124	Phase 2	Nemvaleukin Alfa Subcutaneous;Nemvaleukin Alfa Intravenous
26	Phase II Trial of mTOR Inhibitor Temsirolimus Combined With MEK Inhibitor AZD 6244 in Patients With BRAF Mutant Stage IV Melanoma	Terminated	NCT01166126	Phase 2	temsirolimus;selumetinib
27	Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.	Withdrawn	NCT03758729	Phase 2	Nivolumab
28	A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma	Withdrawn	NCT03220009	Phase 2
29	A Dose Ranging Trial of Adenovirus CCL-21 Transduced MART-1/gp100 Peptide-Pulsed Dendritic Cells Matured Using Cytokines for Patients With Chemotherapy-Resistant Metastatic Melanoma	Completed	NCT00798629	Phase 1
30	Molecular Characterization of Primary Mucosal Melanoma	Active, not recruiting	NCT03319693

Search NIH Clinical Center for Mucosal Melanoma

Sources

Genetic Tests for Mucosal Melanoma

Genetic tests related to Mucosal Melanoma:

#	Genetic test	Affiliating Genes
1	Mucosal Melanoma ²⁹

Sources

Anatomical Context for Mucosal Melanoma

The Foundational Model of Anatomy Ontology organs/tissues related to Mucosal Melanoma:

¹⁹

Mucosal Membranes Lining The Respiratory

MalaCards organs/tissues related to Mucosal Melanoma:

⁴⁰

Skin, Lymph Node, Tongue, Brain, Tonsil, Eye, Small Intestine

Sources

Publications for Mucosal Melanoma

Articles related to Mucosal Melanoma:

(show top 50) (show all 826)

#	Title	Authors	PMID	Year
1	Recurrence of mucosal melanoma in Li-Fraumeni syndrome: A follow-up of an index case. ⁶¹	Jebain J...Tyring SK	33732843	2021
2	The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. ⁶¹	Ogata D...Amaria RN	33686688	2021
3	CDK4 and TERT amplification in head and neck mucosal melanoma. ⁶¹	Lyu J...Zhu H	33797827	2021
4	Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma. ⁶¹	Moya-Plana A...Gorphe P	33783056	2021
5	Mucosal Melanoma of the Hard Palate: Surgical Treatment and Reconstruction. ⁶¹	Bondi S...Abati S	33804881	2021
6	Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma. ⁶¹	Broit N...Pritchard AL	33707307	2021
7	BRAFV600E mutation in oral melanocytic nevus and oral mucosal melanoma. ⁶¹	Resende TAC...Gomez RS	33189579	2021
8	Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma. ⁶¹	Shoushtari AN	33492992	2021
9	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. ⁶¹	Buchbinder EI...Hodi FS	33724703	2021
10	Observed progression from melanosis with melanocyte hyperplasia to sinonasal melanoma with distant metastasis and a unique genetic rearrangement. ⁶¹	Salari B...Foreman RK	33694261	2021
11	Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. ⁶¹	Yan X...Guo J	33444116	2021
12	Characterization of Primary Cultures of Normal and Neoplastic Canine Melanocytes. ⁶¹	Sforna M...Brachelente C	33802040	2021
13	Primary sinonasal malignant melanoma with systemic metastasis in a non-gray horse. ⁶¹	Hatai H...Hobo S	33292086	2021
14	Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004 to 2016: striking differences and similarities of two neighbouring countries. ⁶¹	Reyn B...Kukutsch NA	33656221	2021
15	Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma. ⁶¹	Kiniwa Y...Okuyama R	33338202	2021
16	Primary BRAF Mutant Melanoma of the Lung Treated with Immunotherapy and Pulmonary Bilobectomy: A Case Report. ⁶¹	Bernal L...Beltran R	33731665	2021
17	Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients. ⁶¹	Millan-Esteban D...Nagore E	33648909	2021
18	Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases. ⁶¹	Fujisawa Y...Yoshino K	33503528	2021
19	Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. ⁶¹	Sezen D...Lin LL	33795130	2021
20	Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-Kit. ⁶¹	Sabbah M...Journe F	33741716	2021
21	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). ⁶¹	Hodi FS...Hogg D	33234846	2021
22	Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. ⁶¹	Byeon S...Kim ST	33399091	2021
23	Identification of vital genes and pathways associated with mucosal melanoma in Chinese. ⁶¹	Du M...Guo L	33189033	2021
24	Prognostic significance of regression and mitotic rate in head and neck cutaneous melanoma. ⁶¹	Kim E...Khariwala SS	33614938	2021
25	Regional disease control in sinonasal mucosal melanoma: Systematic review and meta-analysis. ⁶¹	De Virgilio A...Spriano G	33151611	2021
26	Do Not Skip the Retroflexion: A Case of Disseminated Anorectal Mucosal Melanoma. ⁶¹	Chittajallu V...Chahal P	33553463	2021
27	Survival and Prognostic Nomogram for Primary Gastrointestinal Melanoma (PGIM): A Population-based Study. ⁶¹	Badakhshi H...Kaul D	33517303	2021
28	Regional lymph node infiltration and thick lesions are associated with poor prognosis in high-risk resected melanomas: A retrospective cohort study. ⁶¹	Anwar SL...Aryandono T	33456772	2021
29	Are our patients doing better? A single institution experience of an evolving management paradigm for sinonasal mucosal melanoma. ⁶¹	Flukes S...Cohen MA	32958401	2021
30	Review of Dermoscopy and Reflectance Confocal Microscopy Features of the Mucosal Melanoma. ⁶¹	De Pascalis A...Cinotti E	33429900	2021
31	The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: Systematic review and meta-analysis. ⁶¹	Grant-Freemantle MC...Clover AJP	32926490	2021
32	Malignant melanoma of urethra in a young female - Case report and Literature review. ⁶¹	Das J...A Badhe B	33716219	2021
33	A Rare Case of Oral Mucosal Amelanotic Melanoma in a 77-year-old Immunocompromised Man. ⁶¹	Cooper H...Miller R	33584964	2021
34	Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study. ⁶¹	Del Fiore P...Mocellin S	33747946	2021
35	Ultraviolet radiation drives mutations in a subset of mucosal melanomas. ⁶¹	Mundra PA...Marais R	33431815	2021
36	Malignant tumors of the hard palate: Report of 4 cases and review of the literature. ⁶¹	Hammouda Y...Mahtar M	33360635	2021
37	Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. ⁶¹	Rose AAN...Spreafico A	33483342	2021
38	An Overview of Liver Directed Locoregional Therapies. ⁶¹	Hoppener DJ...Verhoef C	33220800	2021
39	NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications. ⁶¹	Forschner A...Bonzheim I	32656925	2020
40	The molecular profile of mucosal melanoma. ⁶¹	Mikkelsen LH...Heegaard S	33156594	2020
41	Variable Expression of S100 Protein in Sinonasal Malignant Mucosal Melanoma: A Potential Diagnostic Pitfall. ⁶¹	Xu X...Bishop JA	32239440	2020
42	Oral mucosal melanoma: Case report. ⁶¹	Lin CW...Chiang CP	33505631	2020
43	Long interspersed nucleotide element-1 hypomethylation in canine malignant mucosal melanoma. ⁶¹	Ishizaki T...Kimura T	32187810	2020
44	Response to PD-1 blockade in a patient with mucosal melanoma of the middle ear: Case report. ⁶¹	Komatsuda H...Harabuchi Y	33363953	2020
45	Dermatoscopy of melanoma according to type, anatomic site and stage: a 2020 update. ⁶¹	Lallas A...Apalla Z	33314891	2020
46	Systemic Therapy for Melanoma: ASCO Guideline. ⁶¹	Seth R...Funchain P	32228358	2020
47	Survival of oral mucosal melanoma according to treatment, tumour resection margin, and metastases. ⁶¹	Chae YS...Lee JH	32586691	2020
48	Primary tumor volume as a predictor of distant metastases and survival in patients with sinonasal mucosal melanoma. ⁶¹	Flukes S...Cohen MA	32737953	2020
49	Development of Merkel Cell Carcinoma and Squamous Cell Carcinoma During Treatment With Pembrolizumab for Metastatic Mucosal Melanoma. ⁶¹	Hajar T...Leitenberger JJ	31584527	2020
50	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. ⁶¹	Edwards J...Wilmott JS	32917657	2020

Sources

Genes for Mucosal Melanoma

Genes related to Mucosal Melanoma (0 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	15.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	15.41	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	GNAQ	G Protein Subunit Alpha Q	Protein Coding	14.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	GNA11	G Protein Subunit Alpha 11	Protein Coding	14.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	CD274	CD274 Molecule	Protein Coding	13.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	MITF	Melanocyte Inducing Transcription Factor	Protein Coding	13.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	NF1	Neurofibromin 1	Protein Coding	12.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	IL2	Interleukin 2	Protein Coding	12.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	12.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	TERT	Telomerase Reverse Transcriptase	Protein Coding	12.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	SPRED1	Sprouty Related EVH1 Domain Containing 1	Protein Coding	12.33	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	IFNA2	Interferon Alpha 2	Protein Coding	12.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	TP53	Tumor Protein P53	Protein Coding	12.09	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	MAGEC1	MAGE Family Member C1	Protein Coding	11.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	CTAG1B	Cancer/Testis Antigen 1B	Protein Coding	11.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	IFNA1	Interferon Alpha 1	Protein Coding	11.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	BAP1	BRCA1 Associated Protein 1	Protein Coding	11.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	MAGEC2	MAGE Family Member C2	Protein Coding	11.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	11.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	KDR	Kinase Insert Domain Receptor	Protein Coding	11.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Mucosal Melanoma

Sources

Expression for Mucosal Melanoma

Search GEO for disease gene expression data for Mucosal Melanoma.

Sources

Pathways for Mucosal Melanoma

Pathways related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 42)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	14.02	VEGFA TP53 SPRED1 NRAS NF1 KIT
2	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.8	VEGFA TP53 NRAS NF1 KIT IL2
3	TGF-Beta Pathway ⁶³ Show member pathways JAK-STAT Pathway ⁶³ JNK Pathway ⁶³ MAPK Family Pathway ⁶³ Regulation of eIF4 and p70S6K ⁶³ SOCS Pathway ⁶³	13.48	VEGFA TP53 NRAS KIT IL2 IFNA2
4	Response to elevated platelet cytosolic Ca2+ ⁶⁵ Show member pathways Disinhibition of SNARE formation ⁶⁵ Hemostasis ⁶⁵ Platelet activation, signaling and aggregation ⁶⁵ Platelet degranulation ⁶⁵	13.25	VEGFA TP53 NRAS IL2 IFNA2 IFNA1
5	Toll-like Receptor Signaling Pathway ³⁶ ¹ Show member pathways Chagas disease ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ Lipid and atherosclerosis ³⁶ Regulation of toll-like receptor signaling pathway ¹	13.07	TP53 NRAS IL2 IFNA2 IFNA1 GNAQ
6	Phospholipase-C Pathway ⁶³ Show member pathways PTEN Pathway ⁶³	13.03	TP53 NRAS KIT IL2 GNA11 BRAF
7	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	12.96	VEGFA TP53 SPRED1 NRAS NF1 KIT
8	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.82	VEGFA TP53 NRAS KIT CDKN2A BRAF
9	Development Angiotensin activation of ERK ²³ Show member pathways Cell adhesion Integrin inside-out signaling ²³ Development ACM2 and ACM4 activation of ERK ²³ Development Angiotensin signaling via PYK2 ²³ Development EDNRB signaling ²³ Development EPO-induced MAPK pathway ²³ Development G-Proteins mediated regulation MARK-ERK signaling ²³ Signal transduction IP3 signaling ²³	12.8	NRAS KIT GNAQ GNA11 BRAF
10	Aldosterone synthesis and secretion ³⁶ Show member pathways Ca2+ activated K+ channels ⁶⁵ Cortisol synthesis and secretion ³⁶ Cushing syndrome ³⁶ Insulin secretion ³⁶ Melanogenesis ³⁶ Thyroid hormone synthesis ³⁶	12.77	NRAS MITF KIT GNAQ GNA11 CDKN2A
11	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	12.76	VEGFA TP53 TERT NRAS KIT IL2
12	MAPK signaling pathway ³⁶ ¹	12.7	VEGFA TP53 NRAS NF1 KIT BRAF
13	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.69	TP53 TERT NRAS KIT CDKN2A BRAF
14	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	12.66	VEGFA TP53 NRAS IFNA2 IFNA1 GNAQ
15	Ras signaling pathway ³⁶ Show member pathways Rap1 signaling pathway ³⁶	12.65	VEGFA NRAS NF1 KIT GNAQ BRAF
16	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ³⁶ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.58	VEGFA TP53 NRAS NF1 BRAF
17	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.57	TP53 NRAS NF1 MITF CDKN2A BRAF
18	Immune response Role of DAP12 receptors in NK cells ²³ Show member pathways Immune response CD16 signaling in NK cells ²³ Natural killer cell mediated cytotoxicity ³⁶	12.46	NRAS IL2 IFNA2 IFNA1 BRAF
19	Proteoglycans in cancer ³⁶	12.27	VEGFA TP53 NRAS BRAF
20	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²³ Show member pathways Activation of the AP-1 family of transcription factors ⁶⁵ Immune response Oncostatin M signaling via MAPK in human cells ²³ MAPK Cascade ¹ Nanoparticle-mediated activation of receptor signaling ¹ Oncostatin M Signaling Pathway ¹	12.27	VEGFA TP53 NRAS BRAF
21	Human T-cell leukemia virus 1 infection ³⁶	12.25	TP53 TERT NRAS IL2 CDKN2A
22	Pathways in cancer ³⁶	12.16	VEGFA TP53 TERT NRAS MITF KIT
23	Immune response IFN alpha/beta signaling pathway ²³ Show member pathways Cytokine Network ⁶³ Interferon alpha/beta signaling ⁶⁵ Regulation of IFNA signaling ⁶⁵	12.12	TP53 TERT KIT IL2 IFNA2 IFNA1
24	Integrated Breast Cancer Pathway ¹	12.11	VEGFA TP53 NF1 BRAF
25	UVA-Induced MAPK Signaling ⁶³ Show member pathways UVB-Induced MAPK Signaling ⁶³	12.03	TP53 NRAS GNAQ GNA11
26	MAP Kinase Signaling ⁴	11.93	NRAS NF1 GNAQ BRAF
27	Gap junction ³⁶	11.81	NRAS GNAQ GNA11
28	Corticotropin-releasing hormone signaling pathway ¹	11.81	IL2 GNAQ GNA11 BRAF
29	Glioblastoma Multiforme ⁶³	11.81	TP53 NRAS NF1 CDKN2A BRAF
30	VEGF Pathway (Tocris) ⁶⁹ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.78	NRAS KIT BRAF
31	Dendritic Cells Developmental Lineage Pathway ⁶⁴	11.72	KIT IL2 IFNA2
32	Commom Cytokine Receptor G Chain Siganaling Pathway ⁶⁶	11.71	NRAS IL2 BRAF
33	Central carbon metabolism in cancer ³⁶	11.69	TP53 NRAS KIT
34	G-protein signaling_RhoA regulation pathway ²³	11.69	NRAS IL2 GNAQ GNA11 BRAF
35	Mitophagy - animal ³⁶	11.67	TP53 NRAS MITF
36	GnRH secretion ³⁶	11.64	NRAS GNAQ GNA11
37	HIF1Alpha Pathway ⁶³	11.56	VEGFA TP53 CDKN2A
38	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.53	TP53 IL2 CDKN2A
39	Aryl Hydrocarbon Receptor ¹	11.49	VEGFA NRAS NF1
40	Long-term depression ³⁶	11.48	NRAS GNAQ GNA11 BRAF
41	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.42	VEGFA NRAS BRAF
42	Bladder cancer ³⁶ ¹	11.22	VEGFA TP53 NRAS CDKN2A BRAF

Sources

GO Terms for Mucosal Melanoma

Biological processes related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.15	VEGFA NRAS NF1 KIT IFNA1 GNAQ
2	negative regulation of apoptotic process	GO:0043066	9.91	VEGFA TP53 TERT MITF IL2 BRAF
3	positive regulation of gene expression	GO:0010628	9.88	VEGFA TP53 MITF KIT CDKN2A BRAF
4	regulation of cell proliferation	GO:0042127	9.86	TP53 MITF KIT BRAF
5	B cell differentiation	GO:0030183	9.76	KIT IFNA2 IFNA1
6	negative regulation of protein kinase activity	GO:0006469	9.67	SPRED1 NF1 GNAQ CDKN2A
7	visual learning	GO:0008542	9.65	NF1 KIT BRAF
8	pigmentation	GO:0043473	9.63	NF1 MITF KIT
9	Ras protein signal transduction	GO:0007265	9.62	TP53 NRAS NF1 CDKN2A
10	negative regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903799	9.6	TP53 TERT
11	developmental pigmentation	GO:0048066	9.59	KIT GNA11
12	somatic stem cell division	GO:0048103	9.58	KIT CDKN2A
13	phototransduction, visible light	GO:0007603	9.57	GNAQ GNA11
14	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.56	VEGFA KIT IL2 IFNA2
15	entrainment of circadian clock	GO:0009649	9.55	GNAQ GNA11
16	negative regulation of neuroblast proliferation	GO:0007406	9.54	TP53 NF1
17	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	9.52	VEGFA TP53
18	myeloid progenitor cell differentiation	GO:0002318	9.51	KIT BRAF
19	cytokine-mediated signaling pathway	GO:0019221	9.43	VEGFA TP53 KIT IL2 IFNA2 IFNA1
20	replicative senescence	GO:0090399	9.33	TP53 TERT CDKN2A
21	MAPK cascade	GO:0000165	9.1	SPRED1 NRAS NF1 KIT IL2 BRAF

Molecular functions related to Mucosal Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.62	VEGFA TP53 TERT SPRED1 NRAS NF1
2	cytokine activity	GO:0005125	9.56	VEGFA IL2 IFNA2 IFNA1
3	MDM2/MDM4 family protein binding	GO:0097371	9.16	TP53 CDKN2A
4	type 2A serotonin receptor binding	GO:0031826	8.96	GNAQ GNA11

Sources

Sources for Mucosal Melanoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia